EPFL spin-off Inkocell Therapeutics, a Swiss biotech startup developing next-generation cell therapies, has secured CHF 150,000 from Venture Kick. The funding will accelerate the development of Inkocell’s first-in-class NK-tailored CAR (chimeric antigen receptor) technology, designed to create effective, safe, off-the-shelf, and affordable therapies for patients with life-threatening diseases..

EPFL分拆公司Inkocell Therapeutics是一家开发下一代细胞疗法的瑞士生物技术初创公司，已获得Venture Kick提供的150,000瑞士法郎资金。这笔资金将加速Inkocell公司首创的NK定制CAR（嵌合抗原受体）技术的开发，该技术旨在为患有致命疾病的患者提供有效、安全、现成且价格合理的治疗方案。

Over the past decade, engineered T-cell therapies (CAR-T) have transformed cancer treatment and brought cures to some patients who previously had no options. But these therapies are complex to manufacture, extremely costly, and can trigger dangerous side effects. Not all patients respond, leaving a large group still without effective treatments..

在过去的十年中，工程化T细胞疗法（CAR-T）已经改变了癌症治疗，并为一些以前没有选择的患者带来了治愈的希望。但这些疗法制造复杂、成本极高，并可能引发危险的副作用。并非所有患者都有反应，因此仍有大批患者缺乏有效的治疗手段。

Inkocell Therapeutics

因科赛尔治疗学

is addressing these challenges by engineering a new type of therapy based on Natural Killer (NK) cells—immune cells naturally specialized in detecting and destroying abnormal or diseased cells. By equipping NK cells with its proprietary CAR technology, Inkocell is building therapies that are scalable, safer, and available “off the shelf” without the need for personalized manufacturing..

通过设计一种基于自然杀伤（NK）细胞的新型疗法来应对这些挑战——这种免疫细胞天然擅长发现和摧毁异常或病变细胞。通过为其配备自家的CAR技术，Inkocell正在构建可扩展、更安全且无需个性化制造即可“现成”使用的疗法。

Inkocell’s first programs focus on:

Inkocell的首个项目聚焦于：

B-cell malignancies: these are blood cancers such as leukemia, lymphoma, and multiple myeloma, which together affect over 500,000 patients every year worldwide. While CAR-T therapies have helped some patients, many relapse or cannot access them because of high costs and limited availability.

B细胞恶性肿瘤：这些是血液癌症，如白血病、淋巴瘤和多发性骨髓瘤，每年在全球范围内影响超过50万名患者。尽管CAR-T疗法帮助了一些患者，但许多患者因高昂的费用和有限的可用性而复发或无法获得治疗。

Solid tumors with therapy resistance: more than 10 million patients annually face tumors protected by the tumor stroma—the “shield” of normal cells and tissue around a tumor that makes it harder for treatments to reach the cancer. Inkocell’s CAR-NK approach is designed to break through this shield and attack the cancer directly..

实体瘤具有治疗抗性：每年有超过1000万患者面临受肿瘤基质保护的肿瘤——肿瘤周围正常细胞和组织形成的“屏障”，使治疗更难以到达癌症部位。Inkocell的CAR-NK方法旨在突破这一屏障并直接攻击癌症。

Applications going beyond oncology

超越肿瘤学的应用

Beyond oncology, the same NK-tailored CAR technology could be applied to autoimmune diseases (where the immune system attacks the body’s own tissues) and fibrotic diseases (characterized by organ-damaging scar tissue), opening the door to treatments for millions more patients.

除了肿瘤学之外，同样的NK定制CAR技术可以应用于自身免疫疾病（免疫系统攻击身体自身组织）和纤维化疾病（以损害器官的疤痕组织为特征），为数百万患者打开了治疗的大门。

With the CHF 150,000 investment from

随着来自CHF 150,000的投资

Venture Kick

风险投资启动

, Inkocell will strengthen its business development and accelerate preparations for clinical testing, bringing its therapies closer to patients.

Inkocell将加强其业务发展并加快临床试验的准备工作，使其疗法更接近患者。

On Venturekick picture: CEO Mathieu Girardin and CSO Angela Madurga Alonso

在Venturekick的图片中：首席执行官马修·吉拉丹和首席科学官安吉拉·马杜尔加·阿隆索